1-7 of 7
Ronald S. Cheung
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Lower-Intensity CPX-351 + Venetoclax for Patients with Newly Diagnosed Acute Myeloid Leukemia Who Are Unfit for Intensive Chemotherapy: Post Hoc Analysis By Disease Risk Subgroups

Tara L. Lin, Praneeth Baratam, Robert K. Stuart, Roland B. Walter, Eric S. Winer, Stefan Faderl, Vijayalakshmi Chandrasekaran, Divya Chakravarthy, Ronald S. Cheung, Vinod A. Pullarkat
Journal: Blood
Blood (2022) 140 (Supplement 1): 3280–3281.
https://doi.org/10.1182/blood-2022-159635
Published: 2022
Journal Articles

V-FAST Master Trial: Subgroup Analysis of Outcomes with CPX-351 Plus Midostaurin in Adults with Newly Diagnosed Acute Myeloid Leukemia By FLT3 Mutation Type

James McCloskey, Vinod A. Pullarkat, Gabriel N. Mannis, Tara L. Lin, Stephen A Strickland, Amir T. Fathi, Stefan Faderl, Divya Chakravarthy, Yana Lutska, Vijayalakshmi Chandrasekaran, Ronald S. Cheung, Mark J. Levis
Journal: Blood
Blood (2022) 140 (Supplement 1): 3312–3314.
https://doi.org/10.1182/blood-2022-159680
Published: 2022
Journal Articles

Preliminary Results By Age Group of Treatment with CPX-351 Plus Venetoclax in Adults with Newly Diagnosed AML: Subgroup Analysis of the V-FAST Phase 1b Master Trial

Vinod A. Pullarkat, Mark Levis, Gabriel N. Mannis, Stephen A Strickland, Tara L. Lin, Stefan Faderl, Divya Chakravarthy, Vijayalakshmi Chandrasekaran, Ronald S. Cheung, Harry P. Erba
Journal: Blood
Blood (2021) 138 (Supplement 1): 1268.
https://doi.org/10.1182/blood-2021-148054
Published: 2021
Journal Articles

CPX-351, a Dual-Drug Liposomal Formulation, Alleviates the Cardiotoxicity of Daunorubicin and Cytarabine to Induced Human Pluripotent Stem Cell-Derived Cardiomyocytes

Marie C. Fortin, Andrew LaCroix, Qi Wang, Ronald S. Cheung
Journal: Blood
Blood (2021) 138 (Supplement 1): 4352.
https://doi.org/10.1182/blood-2021-147993
Published: 2021
Journal Articles

Phase 1b Study of Lower-Dose CPX-351 Plus Venetoclax As First-Line Treatment for Patients with AML Who Are Unfit for Intensive Chemotherapy: Preliminary Safety and Efficacy Results

Geoffrey L. Uy, Vinod A. Pullarkat, Praneeth Baratam, Robert K. Stuart, Stefan Faderl, Vijayalakshmi Chandrasekaran, Qi Wang, Divya Chakravarthy, Ronald S. Cheung, Tara L. Lin
Journal: Blood
Blood (2021) 138 (Supplement 1): 2316.
https://doi.org/10.1182/blood-2021-148455
Published: 2021
Journal Articles

V-FAST: A Phase 1b Master Trial to Investigate CPX-351 Combined with Various Targeted Agents in Patients with Previously Untreated Acute Myeloid Leukemia

Tara Lin, MD, Gabriel N. Mannis, MD, Harry P. Erba, Mark Levis, MD PhD, Heng Zou, Stefan Faderl, Ronald S. Cheung, Vinod A. Pullarkat, MD
Journal: Blood
Blood (2020) 136 (Supplement 1): 26–28.
https://doi.org/10.1182/blood-2020-136868
Published: 2020
Journal Articles

Disparate Requirements for the Phosphorylation of Distinct Sites on the Fanconi Anemia Group I Protein

Ronald S. Cheung, MD PhD, Maria Castella, PhD, Toshiyasu Taniguchi, MD PhD
Journal: Blood
Blood (2014) 124 (21): 358.
https://doi.org/10.1182/blood.V124.21.358.358
Published: 2014